Gary Giarratano joins Radient Pharmaceuticals

Takes position of director of North American sales and marketing

Radient Pharmaceuticals Corporation (RPC) has appointed Gary Giarratano as director of North American sales and marketing. He will also be responsible for managing sales of the firm’s Onko-Sure in vitro diagnostic (IVD) cancer test.

Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.

‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.

You may also like

Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Regulatory

Roca secures EMA recognition of radiation maculopathy as a distinct indication and Orphan Drug Designation

Roca Therapeutics (Roca) announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, to treat radiation maculopathy
Manufacturing

Suncombe launches compact pH neutralisation systems for labs and small facilities

Expanded SUNpH range delivers compliance and performance in space-limited settings
Regulatory

Filter manufacturer maintains official seal of approval for health and safety

Inspectors from health and safety standards body BSI have praised a process filter maker’s “thorough and well-organised approach” to workplace safety management
Manufacturing

One family’s journey from diagnosis to gene replacement therapy

How the Krueger family, supported by clinicians, researchers, and manufacturers, accelerated a novel treatment for ultra-rare NEDAMSS in just 14 months
Regulatory

WuXi Biologics Ireland receives EMA approval to manufacture an innovative biologic

This approval adds to WuXi Biologics’ multiple facilities, which have received EMA and FDA approvals for commercial manufacturing of the same product since 2023
Manufacturing

Scalable chemistry and cross-sector expertise at CARBOGEN AMCIS Manchester

How the Manchester site delivers flexible solutions from early-phase synthesis to cosmetics GMP
Subscribe now